Welcome to our dedicated page for Tonix Pharmaceuticals Holding SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Tonix Pharmaceuticals Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Tonix Pharmaceuticals Holding's regulatory disclosures and financial reporting.
Tonix Pharmaceuticals Holding Corp. (TNXP) director and Chief Executive Officer Seth Lederman reported buying common stock on August 27, 2026. An IRA account associated with him purchased 2,000 shares of common stock at $13.79 per share in an open-market or private transaction, held as indirect ownership. After this purchase, the IRA account held 11,005 shares. Separate from this, he also reported 20,001 shares held directly and 1 share held indirectly through Lederman & Co., for which he may be deemed a control person.
Tonix Pharmaceuticals Holding Corp. (TNXP) director Richard H. Bagger reported purchasing 1,000 shares of the company’s common stock on August 20, 2026. The shares were bought at a price of $12.60 per share, and he now holds 1,000 shares of Tonix common stock directly.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported that on August 18, 2026, its Board of Directors appointed Dr. Seth Lederman, the company’s President, Chief Executive Officer and Chairman of the Board, as Interim Chief Medical Officer. Dr. Lederman, age 69, has held his existing leadership roles since October 2011 and will continue to serve in all of these positions concurrently.
The company states there are no arrangements or understandings with any other person related to his appointment, and no family relationships between Dr. Lederman and any director or executive officer. Tonix publicly announced his appointment as Interim Chief Medical Officer on the same date.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Tonix Pharmaceuticals Holding Corp. common stock. They report control over 814,801 shares of Common Stock, including 615,025 shares issuable upon exercise of warrants, representing 4.9% of the class.
The ownership percentage is based on 15,940,801 shares of Common Stock outstanding as of May 8, 2026 and assumes exercise of the warrants held by funds managed by Sirenia. Voting and dispositive powers over these shares are reported on a shared basis, with no sole voting or dispositive power.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC report beneficial ownership of 882,595 shares of Tonix Pharmaceuticals Holding Corp. common stock, representing 5.54% of the class. They report shared voting power over 866,867 shares and shared dispositive power over 882,595 shares, with no sole voting or dispositive power. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC, and the Schedule 13G is filed on behalf of both entities.
Tonix Pharmaceuticals Holding Corp. reported strong early commercialization of its CNS portfolio but continued heavy losses for the quarter ended June 30, 2026. Net product revenue was $13.5 million for the quarter and $20.4 million for the first half of 2026, up sharply from 2025, driven mainly by the U.S. launch of TONMYA for fibromyalgia and migraine products Zembrace SymTouch and Tosymra.
Operating expenses increased substantially as the company scaled commercial and R&D activities. For the first half of 2026, research and development expense was $37.6 million and selling, general and administrative expense was $64.6 million, leading to a net loss of $80.7 million for the six-month period. Cash used in operating activities was $84.6 million.
Tonix ended June 30, 2026 with $176.2 million in cash and cash equivalents, total assets of $254.1 million and working capital of approximately $172.6 million, supported by $53.6 million of ATM equity proceeds in the first half. Management expects existing cash plus subsequent equity raises to fund operations into early second quarter 2027, but not for 12 months from the financial statement issuance date, and disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern. The company continues to advance a broad pipeline across CNS, infectious disease, immunology and rare diseases, including Phase 2 and preclinical programs.
Tonix Pharmaceuticals reported strong second quarter 2026 growth in commercial performance driven by TONMYA, its fibromyalgia treatment launched in November 2025. Net product revenue was $13.5 million for the quarter, up from $2.0 million a year earlier, including $11.0 million from TONMYA and $2.5 million from migraine products. TONMYA net sales increased approximately 197% quarter-over-quarter and total prescriptions reached 12,592, doubling versus the prior quarter, with refills up 207%.
Payer coverage expanded meaningfully, with TONMYA now reaching about 136 million covered lives (43% of U.S. covered lives) across commercial, managed Medicare, and Medicaid, expected to rise to roughly 145 million on January 1, 2027. Tonix is growing its TONMYA sales force to about 150 representatives by September 2026. The company continues to invest heavily in its pipeline, including Phase 2 programs for TNX-102 SL in major depressive disorder and adaptive Phase 2 planning for TNX-4800 in Lyme disease prevention. These initiatives contributed to a net loss of $40.6 million for the quarter and net cash used in operating activities of $84.6 million for the first half of 2026, funded by $176.2 million in cash and cash equivalents as of June 30, 2026 and additional ATM proceeds.
Tonix Pharmaceuticals Holding Corp. reported receiving official minutes from a Type C meeting with the U.S. FDA outlining alignment on an adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody to prevent Lyme disease in U.S. adults.
The planned randomized, placebo-controlled study would enroll approximately 3,300 adults in Lyme-endemic areas over two seasons, randomizing participants 1:1 to TNX-4800 450 mg subcutaneously or placebo in a two-dose regimen three months apart. The primary efficacy endpoint is Lyme disease prevention at six months after the first dose, with a key secondary endpoint at three months, and a primary safety objective of assessing safety and tolerability over 52 weeks.
Tonix plans to start the Phase 2 study in the first quarter of 2027 and expects most enrollment in 2028, with possible extension to 2029 if the attack rate is lower than expected. TNX-4800 is Fc-modified for extended half-life, is supported by non-human primate data showing high preventive efficacy, and is covered by a U.S. patent expiring in 2036, alongside potential 12-year biologic exclusivity.
Tonix Pharmaceuticals Holding Corp. reports an upcoming leadership change. On July 20, 2026, Dr. Gregory M. Sullivan informed the company that he will retire from his role as Chief Medical Officer, effective August 20, 2026. This reflects a planned transition in a key executive position.
Tonix Pharmaceuticals Holding Corp. entered into an agreement with a pharmacy benefit manager to provide TONMYA coverage for Medicare Part D beneficiaries, effective January 1, 2027. The agreement adds coverage for approximately 9 million Medicare lives, or 16% of about 55 million Medicare beneficiaries in the U.S.
Combined with two previously announced commercial coverage agreements and Medicaid availability in most states representing approximately 73 million lives, pharmacy coverage for TONMYA is expected to reach about 145 million covered lives on January 1, 2027, or 46% of 314 million covered lives. Tonix plans to expand its sales force by 50 representatives by mid–third quarter 2026, bringing the total to around 150 to support the product’s launch.
TONMYA, a 2.8 mg cyclobenzaprine HCl sublingual tablet, was approved by the FDA on August 15, 2025 for treatment of fibromyalgia in adults, with U.S. patent protection expected to provide market exclusivity until 2034. The disclosure also reiterates extensive safety, contraindication, and use-in-specific-populations information for TONMYA.